Michael Merger

Affiliations

Oncology Medicine, Boehringer Ingelheim International GmbH, Biberach, Germany.

Réseau de co-auteurs

Isabelle Ray-Coquard 1 collaboration

David Cibula 1 collaboration

Mansoor R Mirza 1 collaboration

Alexander Reuss 1 collaboration

Caterina Ricci 1 collaboration

Nicoletta Colombo 1 collaboration

Horst Koch 1 collaboration

Frédéric Goffin 1 collaboration

Antonio González-Martin 1 collaboration

Petronella B Ottevanger 1 collaboration

Klaus Baumann 1 collaboration

Line Bjørge 1 collaboration

Anne Lesoin 1 collaboration

Alexander Burges 1 collaboration

Per Rosenberg 1 collaboration

Martina Gropp-Meier 1 collaboration

Maija Harrela 1 collaboration

Philipp Harter 1 collaboration

Jean-Sébastien Frenel 1 collaboration

Tomas Minarik 1 collaboration

Carmela Pisano 1 collaboration

Annette Hasenburg 1 collaboration

Andreas du Bois 1 collaboration

None None 1 collaboration

F Heitz 1 collaboration

P Harter 1 collaboration

E Åvall-Lundqvist 1 collaboration

A Reuss 1 collaboration

P Pautier 1 collaboration

G Cormio 1 collaboration

N Colombo 1 collaboration

A Reinthaller 1 collaboration

I Vergote 1 collaboration

A Poveda 1 collaboration

P B Ottevanger 1 collaboration

L C Hanker 1 collaboration

A Leminen 1 collaboration

J Alexandre 1 collaboration

U Canzler 1 collaboration

J Sehouli 1 collaboration

J Herrstedt 1 collaboration

B Fiane 1 collaboration

M Merger 1 collaboration

A du Bois 1 collaboration

Michael Merger

Affiliations

Publications (2)

Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer.

Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.

Réseau de co-auteurs